Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sticker Shock: The Debate Over Making Part D Pricing Data Public

This article was originally published in RPM Report

Executive Summary

A Congressional committee is sifting through drug rebate data from 12 big Medicare Part D plans. According to Congress' accounting arm, making the data public will cost the government as much as $10 billion dollars. But industry better be nervous about what happens next.

You may also be interested in...



Paying for Protection: Medicare Rebates May Make Protected Classes Less Safe for Sponsors

Democrats failed in their first attempt to impose price controls in Medicare Part D. But, led by California Rep. Waxman, they may have found a new approach that seems less threatening than price negotiations-rebates for products used by dual eligible patients. And the drugs most likely to be affected are in Part D's six protected classes.

Paying for Protection: Medicare Rebates May Make Protected Classes Less Safe for Sponsors

Democrats failed in their first attempt to impose price controls in Medicare Part D. But, led by California Rep. Waxman, they may have found a new approach that seems less threatening than price negotiations-rebates for products used by dual eligible patients. And the drugs most likely to be affected are in Part D's six protected classes.

Rebates Redux: Medicare Drug Rebates Next?

Drug prices have lost their headline appeal. That has got to be a relief to pharma execs who have pipeline problems and patent expirations to deal with and don't need to be worried about bad publicity egging on Congress to price-control schemes. But there are new threats to drug prices brewing - and one of them is industry's old nemesis: government rebates.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS080257

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel